Use of Fingolimod in the Management of Relapsing-Remitting Multiple Sclerosis: Experience from Latin America

about

Use of Fingolimod in the Management of Relapsing-Remitting Multiple Sclerosis: Experience from Latin America

Item

http://www.wikidata.org/entity/Q35907969

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Use of Fingolimod in the Manag ...... Experience from Latin America

@ast

Use of Fingolimod in the Manag ...... Experience from Latin America

@en

type

Item

label

Use of Fingolimod in the Manag ...... Experience from Latin America

@ast

Use of Fingolimod in the Manag ...... Experience from Latin America

@en

prefLabel

Use of Fingolimod in the Manag ...... Experience from Latin America

@ast

Use of Fingolimod in the Manag ...... Experience from Latin America

@en

P1476

Use of Fingolimod in the Manag ...... Experience from Latin America

@en

P2093

Claudia Cárcamo Rodríguez

http://www.w3.org/2001/XMLSchema#string

Enedina M L Oliveira

http://www.w3.org/2001/XMLSchema#string

Jorge Correale

http://www.w3.org/2001/XMLSchema#string

Jose Flores

http://www.w3.org/2001/XMLSchema#string

Juan Garcia Bonitto

http://www.w3.org/2001/XMLSchema#string

P2860

Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms

Multiple sclerosis in Argentina. Systematic review and meta-analysis

Vagomimetic effects of fingolimod: physiology and clinical implications

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Association between parasite infection and immune responses in multiple sclerosis

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.

Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

P2888

s12325-015-0226-0

P304

612-625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S12325-015-0226-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280058086

http://www.w3.org/2001/XMLSchema#string

P698

26170106

http://www.w3.org/2001/XMLSchema#string

P921

Alcoal

amine

relapsing-remitting multiple sclerosis

P932

4522024

http://www.w3.org/2001/XMLSchema#string